Beam Therapeutics Inc BEAM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
22.24UNCH (UNCH)
Volume
200,243
Close
22.24quote price arrow down-0.29 (-1.29%)
Volume
819,687
52 week range
16.95 - 49.50
Loading...
  • Open21.71
  • Day High22.26
  • Day Low21.63
  • Prev Close22.53
  • 52 Week High49.50
  • 52 Week High Date02/27/24
  • 52 Week Low16.95
  • 52 Week Low Date10/23/23

Key Stats

  • Market Cap1.831B
  • Shares Out82.31M
  • 10 Day Average Volume1.25M
  • Dividend-
  • Dividend Yield-
  • Beta1.88
  • YTD % Change-18.3

KEY STATS

  • Open21.71
  • Day High22.26
  • Day Low21.63
  • Prev Close22.53
  • 52 Week High49.50
  • 52 Week High Date02/27/24
  • 52 Week Low16.95
  • 52 Week Low Date10/23/23
  • Market Cap1.831B
  • Shares Out82.31M
  • 10 Day Average Volume1.25M
  • Dividend-
  • Dividend Yield-
  • Beta1.88
  • YTD % Change-18.3

RATIOS/PROFITABILITY

  • EPS (TTM)-1.74
  • P/E (TTM)-12.76
  • Fwd P/E (NTM)-4.21
  • EBITDA (TTM)-160.893M
  • ROE (TTM)-16.09%
  • Revenue (TTM)360.911M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-37.33%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Beam Therapeutics Inc

 

Profile

MORE
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it...
John Evans
Chief Executive Officer, Director
Giuseppe Ciaramella Ph.D.
President
Terry-Ann Burrell
Chief Financial Officer, Treasurer
Address
238 Main Street
Cambridge, MA
02142
United States

Top Peers

SYMBOLLASTCHG%CHG
CPRX
Catalyst Pharmaceuticals Inc
14.72-0.42-2.77%
VCYT
Veracyte Inc
20.12-0.91-4.33%
PTGX
Protagonist Therapeutics Inc
27.11+1.32+5.12%
DNA
Ginkgo Bioworks
0.8934-0.0406-4.3469%
ZLAB
Zai Lab Ltd
16.57-0.11-0.66%